lunes, 9 de marzo de 2026

Endocrine Therapies in ER-Positive/HER2-Negative MBC: Understanding Their Benefits and Limitations to Optimize Treatment Selection Authors: Joyce A. O’Shaughnessy, MD; Aditya Bardia, MD, MPH, FASCO

https://www.medscape.org/viewarticle/1003008?src=mkmcmr_driv_stan_mscpedu_260308-OUS-HONC-1003008-cta&sso=true&uac=148436CN

No hay comentarios:

Publicar un comentario